SCHEMBL20768618

SCHEMBL20768618

Cc1cc(C(=O)O)ccc1C(N)CO

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 2/20 0.66
TDP1 Q9NUW8 2/20 0.66
MEN1 O00255 1/20 0.66
CYP1A2 P05177 1/20 0.66
KMT2A Q03164 1/20 0.66
ACE2 Q9BYF1 4/20 0.46
TSHR P16473 2/20 0.42
MYC P01106 1/20 0.42
ESR1 P03372 1/20 0.42
ALOX15 P16050 1/20 0.42
PTPN7 P35236 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CASR P41180 1/20 0.42
ANPEP P15144 2/20 0.41
ENPEP Q07075 1/20 0.41
RARB P10826 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20768617 1.00 GRM1 (0.66) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL19347921 0.81 CA1 (0.50) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL20768595 0.81 CA1 (0.50) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL29242326 0.81 GRM1 (0.72) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL20768593 0.80 TSHR (0.52) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL20768576 0.80 GRM1 (0.45) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL20768577 0.80 GRM1 (0.45) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL20768592 0.80 TSHR (0.52) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL1078997 0.79 GRM1 (1.00) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL661700 0.79 GRM1 (1.00) GRM1TDP1MEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-11-02 US disclosed
EP-4234552-A2 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-3426244-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-12-27 US disclosed
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2022-01-20 US disclosed
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD GRM1 2815/4885TDP1 832/4885MEN1 3285/4885
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD GRM1 2815/4885TDP1 832/4885MEN1 3285/4885
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD GRM1 2815/4885TDP1 832/4885MEN1 3285/4885
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD GRM1 2815/4885TDP1 832/4885MEN1 3285/4885
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD GRM1 2815/4885TDP1 832/4885MEN1 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.